Post on 02-Oct-2020
University of Groningen
Antibody imaging as biomarker in early cancer drug development and treatmentLamberts, Laetitia Elisabeth
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite fromit. Please check the document version below.
Document VersionPublisher's PDF, also known as Version of record
Publication date:2016
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):Lamberts, L. E. (2016). Antibody imaging as biomarker in early cancer drug development and treatment.Rijksuniversiteit Groningen.
CopyrightOther than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of theauthor(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policyIf you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediatelyand investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons thenumber of authors shown on this cover page is limited to 10 maximum.
Download date: 09-02-2021
Antibody Positron Emission Tomography Imaging inAnticancer Drug DevelopmentLaetitia E. Lamberts, Simon P. Williams, Anton G.T. Terwisscha van Scheltinga, Marjolijn N. Lub-de Hooge,Carolien P. Schröder, Jourik A. Gietema, Adrienne H. Brouwers, and Elisabeth G.E. de Vries
Laetitia E. Lamberts, Anton G.T.Terwisscha van Scheltinga, Marjolijn N.Lub-de Hooge, Carolien P. Schröder,Jourik A. Gietema, Adrienne H. Brouw-ers, and Elisabeth G.E. de Vries, Univer-sity of Groningen, University MedicalCenter Groningen, Groningen, the Neth-erlands; and Simon P. Williams, Genen-tech, South San Francisco, CA.
Published online ahead of print atwww.jco.org on March 16, 2015.
Terms in blue are defined in the glos-sary, found at the end of this articleand online at www.jco.org.
Authors’ disclosures of potentialconflicts of interest are found in thearticle online at www.jco.org. Authorcontributions are found at the end ofthis article.
Corresponding author: Elisabeth G.E. deVries, MD, PhD, Department of MedicalOncology, University of Groningen,University Medical Center Groningen,P.O. Box 30.001, 9700 RB Groningen,the Netherlands; e-mail: e.g.e.de.vries@umcg.nl.
© 2015 by American Society of ClinicalOncology
0732-183X/15/3313w-1491w/$20.00
DOI: 10.1200/JCO.2014.57.8278
A B S T R A C T
More than 50 monoclonal antibodies (mAbs), including several antibody–drug conjugates, are inadvanced clinical development, forming an important part of the many molecularly targetedanticancer therapeutics currently in development. Drug development is a relatively slow andexpensive process, limiting the number of drugs that can be brought into late-stage trials.Development decisions could benefit from quantitative biomarkers, enabling visualization of thetissue distribution of (potentially modified) therapeutic mAbs to confirm effective whole-bodytarget expression, engagement, and modulation and to evaluate heterogeneity across lesions andpatients. Such biomarkers may be realized with positron emission tomography imaging ofradioactively labeled antibodies, a process called immunoPET. This approach could potentiallyincrease the power and value of early trials by improving patient selection, optimizing dose andschedule, and rationalizing observed drug responses. In this review, we summarize the availableliterature and the status of clinical trials regarding the potential of immunoPET during earlyanticancer drug development.
J Clin Oncol 33:1491-1504. © 2015 by American Society of Clinical Oncology
INTRODUCTION
Cancer remains a major cause of death worldwide,with annual mortality predicted to reach 11.5 mil-lion by 2030.1 The mainstay of systemic treatmenthas long been DNA-damaging chemotherapy, butmolecular insights have facilitated the developmentof more selective drugs, which are increasingly be-coming part of standard care.2 Many of these arebased on monoclonal antibodies (mAbs), becausethey can combine exquisite target specificity withdesirable safety profiles.3 Even inert mAbs can bemade potent as delivery vehicles with cytotoxins inantibody–drug conjugates (ADCs) or radionuclidesin radioimmunotherapy (RIT).4
More than 200 anticancer mAbs have been inclinical trials, resulting in 13 mAbs, three ADCs, andtwo RIT conjugates being granted marketing ap-proval by the US Food and Drug Administrationand European Medicines Agency. In 2013, morethan 300 mAbs were in clinical development, in-cluding 50 anticancer mAbs, 10 of which are inphase II/III trials.5
Clinical drug development requires enormousresources, but it often disappoints; only 8% of first-in-human anticancer drugs obtained regulatory ap-proval between 1990 and 2006, while clinicaldevelopment time averaged 9 years.6 Knowing
which therapeutic antibody candidates to advanceinto clinical development depends on understand-ing both target and antibody biology in patients. Akey aspect of this biology—target-dependent anti-body tumor uptake—can be quantified throughmolecular imaging in patients.7 The combination ofantibody-based imaging reagents and positronemission tomography (PET), known as immuno-PET, greatly improves on antibody imaging withsingle-photon emitters. ImmunoPET offers supe-rior image quality, exquisite sensitivity, and accuratequantification.7-9 The technology has great potentialto inform decisions in early clinical development byaddressing fundamental questions of drug delivery,dose finding, and target modulation, thereby prior-itizing the right agents.10 In this review, we summa-rize the available literature and the status of clinicaltrials regarding the potential of immunoPET duringearly anticancer drug development.
MABS AND THEIR EFFECTS ON TUMORS
mAbs are multimeric binding proteins (approxi-mately 150 kDa) that are highly specific ligands fortheir cognate antigens (Fig 1A). They can exert ther-apeutic effects in three ways: directly through ago-nistic or antagonistic effects on receptor signalingand turnover, indirectly through effects on tumor
JOURNAL OF CLINICAL ONCOLOGY B I O L O G Y O F N E O P L A S I A
VOLUME 33 � NUMBER 13 � MAY 1 2015
© 2015 by American Society of Clinical Oncology 1491
129.125.175.213Information downloaded from jco.ascopubs.org and provided by at Bibliotheek der Rijksuniversiteit on June 1, 2016 from
Copyright © 2015 American Society of Clinical Oncology. All rights reserved.
vasculature or stroma (Fig 1B), or through recruitment of the immunesystem, with subsequent complement-dependent cytotoxicity orantibody-dependent cellular cytotoxicity (Fig 1C).11,12
More powerful approaches to activate the immune system—immunotherapies—rely on antibodies manipulating specific receptor–ligandinteractionsintheimmunosuppressivetumormicroenvironment.Ipilimumab, for example, blocks cytotoxic T-cell lymphocyte–associatedantigen 4 (CTLA-4) to overcome T-cell anergy. After being registered foruse in patients with melanoma, it resulted in impressive durable re-sponses13 and sparked interest in antibodies against targets such as pro-grammed death receptor 1 (PD-1) and its ligand PD-L1, which have alsoshown durable responses in phase I studies.14-16
Many antibody variants and conjugates, all amenable to study byimmunoPET, have been recognized or engineered, which may have asignificant impact in oncology.17,18 Through a linker moiety, antibodyconjugates combine selective antigen binding with a potent payload:cytotoxic drugs for ADCs or radionuclides for RIT (Figs 1D and 1E).4
The target antigen helps concentrate the potent payload to elicit directcell destruction. Currently, three ADCs are registered: gemtuzumabozogamicin and brentuximab vedotin for treatment of various hema-tologic malignancies and adotrastuzumab emtansine (T-DM1)for human epidermal growth factor 2 (HER2) –positive breast
cancer.19-21 Several RIT agents have been registered, namely iodine-131 (131I) –labeled tositumomab and yttrium-90 (90Y) –ibritumomabtiuxetan in the treatment of non-Hodgkin lymphoma.22 Table 1 listsall currently approved mAbs and conjugates.
The effect of antibodies on tumors typically depends on the tissueconcentration, but this is often unknown. Moreover, proper doseselection can be challenging in situations where blood pharmacoki-netics are a poor predictor of tissue kinetics because of tumor burden,immune status, and other factors.11 ImmunoPET can help directlydetermine antibody tissue kinetics in patient tumor lesions to refineour understanding of dose-response relationships during preclinicaland early clinical trials.
MONITORING TARGET EXPRESSION
Patients likely to benefit from a targeted therapy should exhibittumor-selective expression of the molecular target. Developing andvalidating diagnostic strategies for expression analysis has thereforebecome an important part of drug development. Typically, this is donethrough immunohistochemistry (IHC) or quantitative polymerasechain reaction on tumor biopsies. However, this may be unreliable,
Fc fragment
Fab fragment
Light chain
Heavychain
Variable Hypervariable Constant Regions:
Antibody
Cancercell
Cancercell
Antibody
Cellgrowth
Cellsurvival
Proliferation
NK cell
Attack cancer cell
Granzyme and perforin release
ADC binds to receptor
ADC in plasma
ADC-receptor complexis internalized
Cytotoxic agentis released
Apoptosis
177Lu
177Lu
177Lu
RITRITADC
Linker DM1
LinkerDM1 Linker DM1
A
E
DCB
Fig 1. Design and mode of action of monoclonal antibodies (mAbs). (A) Immunoglobulin G antibodies consist of four polypeptide chains: two identical heavy and twoidentical light chains. Each chain contains variable, antigen-binding regions (Fab), which bind to antigen (drug target), and a constant region (Fc) involved in immunesystem activation. (B) Binding of antibody to antigen (target), causing modulation of downstream signaling by agonistic receptor engagement or antagonistic blocking,eventually leading to inhibition of cell growth, proliferation, and survival. (C) Immune-related cell destruction by antibody-dependent cellular cytotoxicity. Fc part of mAbbinds to Fc receptor on effector cells of immune system (natural killer [NK] cells/lymphocytes), causing immune activation and thereby apoptosis of tumor cell. (D)Structure of antibody–radionuclide (for radioimmunotherapy [RIT]) and antibody–drug conjugates (ADCs). (E) Mode of action of ADC, binding to receptor and causinginternalization of ADC–receptor complex. In lysosomes, ADC and receptor are then degraded, releasing cytotoxic agent, which induces apoptosis of target cell.
Lamberts et al
1492 © 2015 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
129.125.175.213Information downloaded from jco.ascopubs.org and provided by at Bibliotheek der Rijksuniversiteit on June 1, 2016 from
Copyright © 2015 American Society of Clinical Oncology. All rights reserved.
Tabl
e1.
Mon
oclo
nalA
ntib
odie
s,A
ntib
ody–
Dru
gC
onju
gate
s,an
dA
ntib
ody–
Rad
ionu
clid
eC
onju
gate
sA
ppro
ved
for
Can
cer
Trea
tmen
t
Gen
eric
Nam
eTy
peTa
rget
and
Loca
tion
Indi
catio
nsY
ear
ofFD
A/E
MA
App
rova
lM
ode
ofA
ctio
nD
ose
Pat
ient
Sel
ectio
n
Ritu
xim
abC
him
eric
IgG
1C
D20
(Bce
lls)
CLL
,N
HL
(firs
tlin
e)19
97/1
998
CD
Can
dA
DC
CC
LL:
375
mg/
m2
star
ting
dose
,50
0m
g/m
2ne
xtcy
cles
(onc
eev
ery
4w
eeks
);N
HL:
375
mg/
m2
once
ever
y3
wee
ksor
once
ever
y2
mon
ths
infir
stlin
e,on
cepe
rw
eek
inm
onot
hera
py,
once
ever
y3
wee
ksin
com
bina
tion
ther
apy
Bas
edon
dise
ase
stag
ean
dty
peC
D20
posi
tive
Ibrit
umom
abtiu
xeta
n;90Y
-ibrit
umom
abtiu
xeta
n
Mur
ine
IgG
2C
D20
(Bce
lls)
NH
L20
02/2
004
Del
iver
yof
radi
oiso
tope
,in
duci
ngra
diat
ion
dam
age
14.8
(pla
tele
ts�
150,
000/
�L)
or11
.1M
Bq/
kg(p
late
lets
100,
000
to15
0,00
0/�
L)on
days
7to
9of
cycl
eaf
ter
ritux
imab
pret
reat
men
ton
days
1an
d8
Bas
edon
CD
20ex
pres
sion
Tosi
tum
omab
;131I-
tosi
tum
omab
Mur
ine
IgG
2C
D20
(Bce
lls)
NH
L20
03/2
003
Del
iver
yof
radi
oiso
tope
,in
duci
ngra
diat
ion
dam
age;
AD
CC
Tosi
tum
omab
:45
0m
g;131I-
tosi
tum
omab
:35
mg;
0.75
Gy
tota
lbod
yif
plat
elet
s�
150,
000/
�L;
0.65
Gy
tota
lbod
yif
plat
elet
s10
0,00
0to
150,
000/
�L
Bas
edon
CD
20ex
pres
sion
Ofa
tum
umab
Hum
anIg
G1k
CD
20(B
cells
)C
LL20
09/2
010
CD
Can
dA
DC
CS
tart
ing
dose
:30
0m
g;ne
xtdo
ses:
2,00
0m
gon
cepe
rw
eek
for
eigh
tcy
cles
,th
enon
cepe
rm
onth
for
four
cycl
es
Not
avai
labl
e
Obi
nutu
zum
abH
uman
ized
IgG
1C
D20
(Bce
lls)
CLL
2013
/201
2A
DC
CC
ycle
one:
100
mg
onda
y1,
900
mg
onda
y2,
1,00
0m
gon
days
8an
d15
;cy
cles
two
tosi
x:1,
000
mg
once
ever
y4
wee
ks
Not
avai
labl
e
Bre
ntux
imab
vedo
tinC
him
eric
IgG
1co
njug
ated
toM
MA
E
CD
30(T
and
Bce
lls)
HL,
syst
emic
anap
last
icla
rge-
cell
lym
phom
a20
11/2
012
Del
iver
yof
MM
AE
toxi
n,in
duci
ngap
opto
sis
1.8
mg/
kgon
ceev
ery
3w
eeks
Bas
edon
CD
30an
tigen
expr
essi
on
Gem
tuzu
mab
ozog
amic
in�
Hum
aniz
edIg
G4
conj
ugat
edto
calic
heam
icin
CD
33(m
yelo
idce
lls)
AM
L20
00/2
000
(off
mar
ket)
�
Ant
ibod
y–dr
ugco
njug
ate,
indu
cing
apop
tosi
s
—
Ale
mtu
zum
abH
uman
ized
IgG
1C
D52
(lym
phoi
dce
lls)
CLL
2001
/200
1C
DC
and
AD
CC
30m
gda
ily,
thre
etim
espe
rw
eek
for
12w
eeks
Not
avai
labl
e;ev
iden
cesu
gges
ting
patie
nts
with
17p
dele
tion
orp5
3m
utat
ion
bene
fitm
ore2
3
Tras
tuzu
mab
Hum
aniz
edIg
G1
HE
R2
(tum
orce
llm
embr
ane)
BC
,ad
juva
ntan
dm
etas
tatic
adva
nced
gast
ricca
ncer
(firs
tlin
e)
1998
/200
0D
ownr
egul
atio
nof
HE
R2
sign
altr
ansd
uctio
n;A
DC
C
Sta
rtin
gdo
se:
8m
g/kg
;ne
xtdo
ses:
6m
g/kg
once
ever
y3
wee
ksor
4m
g/kg
once
ever
y2
wee
ks
Bas
edon
HE
R2
expr
essi
on(p
ositi
veby
IHC
and/
orFI
SH
)
Tras
tuzu
mab
emta
nsin
eH
uman
ized
IgG
1co
njug
ated
toem
tans
ine
HE
R2
(tum
orce
llm
embr
ane)
BC
2013
/201
3D
eliv
ery
ofem
tans
ine,
indu
cing
apop
tosi
s3.
6m
g/kg
once
ever
y3
wee
ksB
ased
onH
ER
2ex
pres
sion
(pos
itive
byIH
Can
d/or
FIS
H)
Per
tuzu
mab
Hum
aniz
edIg
G1
HE
R2
(tum
orce
llm
embr
ane)
BC
2012
/201
3In
hibi
tion
ofH
ER
2di
mer
izat
ion
Sta
rtin
gdo
se:
840
mg;
next
dose
s:42
0m
gon
ceev
ery
3w
eeks
Bas
edon
HE
R2
expr
essi
on(p
ositi
veby
IHC
and/
orFI
SH
)B
evac
izum
abH
uman
ized
IgG
1V
EG
F(m
icro
envi
ronm
ent)
CR
C,
RC
C,
NS
CLC
(non
squa
mou
s),
GB
M
2004
/200
5In
hibi
tion
ofV
EG
Fsi
gnal
ing
CR
C:
5or
10m
g/kg
once
ever
y2
wee
ksor
7.5
or15
mg/
kgon
ceev
ery
3w
eeks
;R
CC
:10
mg/
kgon
ceev
ery
2w
eeks
;N
SC
LC:
7.5
or15
mg/
kgon
ceev
ery
3w
eeks
Not
avai
labl
e
(con
tinue
don
follo
win
gpa
ge)
Antibody PET Imaging in Anticancer Drug Development
www.jco.org © 2015 by American Society of Clinical Oncology 1493
129.125.175.213Information downloaded from jco.ascopubs.org and provided by at Bibliotheek der Rijksuniversiteit on June 1, 2016 from
Copyright © 2015 American Society of Clinical Oncology. All rights reserved.
Tabl
e1.
Mon
oclo
nalA
ntib
odie
s,A
ntib
ody–
Dru
gC
onju
gate
s,an
dA
ntib
ody–
Rad
ionu
clid
eC
onju
gate
sA
ppro
ved
for
Can
cer
Trea
tmen
t(c
ontin
ued)
Gen
eric
Nam
eTy
peTa
rget
and
Loca
tion
Indi
catio
nsY
ear
ofFD
A/E
MA
App
rova
lM
ode
ofA
ctio
nD
ose
Pat
ient
Sel
ectio
n
Ram
uciru
mab
Fully
hum
anIg
G1
VE
GFR
2(m
icro
envi
ronm
ent)
Gas
tric
canc
er20
14/—
†In
hibi
tion
ofV
EG
Fsi
gnal
ing
8m
g/kg
once
ever
y2
wee
ksN
otav
aila
ble
Cet
uxim
abC
him
eric
IgG
1E
GFR
(tum
orce
llm
embr
ane)
CR
C,
HN
SC
C20
04/2
004
Dow
nreg
ulat
ion
ofE
GFR
sign
alin
g;A
DC
CC
ombi
ned
with
irino
teca
non
ceev
ery
2w
eeks
:50
0m
g/m
2;
mon
othe
rapy
orw
ithiri
note
can
once
ever
y3
wee
ks:
star
ting
dose
,40
0m
g/m
2;
next
dose
s,25
0m
g/m
2
CR
C:
base
don
EG
FRex
pres
sion
(pos
itive
)an
dK
RA
Sm
utat
ion
stat
us(w
ildty
pe);
HN
SC
C(h
igh
EG
FRex
pres
sion
):no
sele
ctio
nP
anitu
mum
abH
uman
IgG
2E
GFR
(tum
orce
llm
embr
ane)
CR
C20
06/2
007
Dow
nreg
ulat
ion
ofE
GFR
sign
alin
g;A
DC
C6
mg/
kgon
ceev
ery
2w
eeks
EG
FRex
pres
sion
(pos
itive
)an
dK
RA
Sm
utat
ion
stat
us(w
ildty
pe)
Ipili
mum
abH
uman
IgG
1k
CTL
A-4
(Tce
lls)
Mel
anom
a20
11/2
011
Indu
ces
imm
une
resp
onse
byC
TLA
-43
mg/
kgon
ceev
ery
3w
eeks
for
tota
lof
four
cycl
esN
otav
aila
ble
Pem
brol
izum
abH
uman
ized
IgG
4k
PD
-1(T
cells
)M
elan
oma
2014
/—In
duce
sim
mun
ere
spon
seby
bloc
king
PD
-L1
and
PD
-1in
tera
ctio
n
10m
g/kg
once
ever
y2
or3
wee
ksN
otav
aila
ble
MP
DL3
280A
Hum
anIg
G1
PD
-L1
(tum
orce
llm
embr
ane)
Bla
dder
canc
er20
14/—
‡In
duce
sim
mun
ere
spon
seby
bloc
king
PD
-L1
and
PD
-1in
tera
ctio
n
15m
g/kg
once
ever
y3
wee
ksup
to1
year
Bas
edon
PD
-L1
expr
essi
on
Cat
umax
omab
Mou
sean
dra
tIg
GE
pCA
M(t
umor
cell)
;C
D3
and
Fc�
Rs
(imm
une
effe
ctor
cells
)
Mal
igna
ntas
cite
s—
/200
9§In
duci
ngim
mun
ere
spon
seIn
crea
sing
from
10to
20to
20to
150
�g
intr
aper
itone
alad
min
istr
atio
n
Not
avai
labl
e
Abb
revi
atio
ns:A
DC
C,a
ntib
ody-
depe
nden
tce
llula
rcy
toto
xici
ty;A
ML,
acut
em
yelo
idle
ukem
ia;B
C,b
reas
tca
ncer
,CD
C,c
ompl
emen
t-de
pend
ent
cyto
toxi
city
;CLL
,chr
onic
lym
phoc
ytic
leuk
emia
;CR
C,c
olor
ecta
lca
ncer
;C
TLA
-4,
cyto
toxi
cT-
lym
phoc
yte–
asso
ciat
edan
tigen
4;E
GFR
,ep
ider
mal
grow
thfa
ctor
rece
ptor
;E
MA
,E
urop
ean
Med
icin
esA
genc
y;E
pCA
M,
epith
elia
lcel
ladh
esio
nm
olec
ule;
Fc�
Rs,
Fcre
cept
orfo
rim
mun
oglo
bulin
G;F
DA
,US
Food
and
Dru
gA
dmin
istr
atio
n;FI
SH
,fluo
resc
ent
insi
tuhy
brid
izat
ion;
GB
M,g
liobl
asto
ma;
HE
R2,
hum
anep
ider
mal
grow
thfa
ctor
rece
ptor
2;H
L,H
odgk
inly
mph
oma;
HN
SC
C,h
ead
and
neck
squa
mou
sce
llca
rcin
oma;
131I,
iodi
ne-1
31;I
gG,i
mm
unog
lobu
linG
;IH
C,i
mm
unoh
isto
chem
istr
y;M
MA
E,m
onom
ethy
laur
ista
tinE
;NH
L,no
n-H
odgk
inly
mph
oma;
NS
CLC
,non
–sm
all-c
elll
ung
canc
er;P
D-1
,pr
ogra
mm
edde
ath
rece
ptor
1;P
D-L
1,pr
ogra
mm
edde
ath
rece
ptor
1lig
and;
RC
C,r
enal
cell
canc
er;V
EG
F,va
scul
aren
doth
elia
lgro
wth
fact
or;V
EG
FR2,
vasc
ular
endo
thel
ialg
row
thfa
ctor
rece
ptor
2;90Y
,ytt
rium
-90.
�G
emtu
zum
aboz
ogam
icin
appr
oval
was
with
draw
nin
Uni
ted
Sta
tes
in20
10w
hen
post
mar
ketin
gst
udie
sin
dica
ted
itdi
dno
tim
prov
esu
rviv
alan
dha
dgr
eate
rto
xici
tyth
anch
emot
hera
pyal
one.
Itco
ntin
ues
tobe
mar
kete
din
Japa
n,an
dre
cent
stud
ies
have
show
nbe
nefit
sin
sele
cted
patie
ntgr
oups
.19
†Ram
uciru
mab
was
gran
ted
orph
anst
atus
byE
MA
in20
12fo
rhe
pato
cellu
lar
carc
inom
aan
dga
stric
canc
er.
‡MD
PL3
280A
was
gran
ted
brea
kthr
ough
ther
apy
desi
gnat
ion
byFD
Ain
May
2014
for
met
asta
ticur
othe
lialb
ladd
erca
ncer
.§C
atum
axom
abw
asgr
ante
dor
phan
stat
usby
FDA
in20
06fo
rov
aria
nca
ncer
and
in20
09fo
rga
stric
canc
er.
Lamberts et al
1494 © 2015 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
129.125.175.213Information downloaded from jco.ascopubs.org and provided by at Bibliotheek der Rijksuniversiteit on June 1, 2016 from
Copyright © 2015 American Society of Clinical Oncology. All rights reserved.
because previously sampled and stored tissue may not representthe current tumor status, and heterogeneity exists between andwithin lesions.24-26
With immunoPET, the presence of an accessible target can bedemonstrated noninvasively in whole-body imaging early in clinicaldevelopment. This permits exploration of the relationships betweenorgan- and lesion-level antibody uptake, tumor heterogeneity, drugeffect, and more conventional biomarkers, which may be taken intolater-stage trials.
Monitoring target expression across all lesions may be partic-ularly pertinent for ADC/RIT agents. This is because their deliveryto the target is based especially on tissue expression patterns, whichmay not represent the oncogenic behavior of the tumor. Conse-quently, lesions without a sufficient target may show poor uptakewhile remaining aggressive and contribute to poor clinical out-comes even when the ADC/RIT agent is locally efficacious in le-sions with sufficient uptake. Comprehensive lesion assessment istherefore required, but this approach (especially serial assessment)is impractical with invasive techniques. As a noninvasive proce-dure, immunoPET avoids this problem.
DEVELOPMENT OF ANTIBODY IMAGING: LABELSAND DETECTION
Early nuclear imaging relied on two-dimensional scintigraphy, whichwas difficult to quantify. In the early 1980s, three-dimensional single-photon emission computed tomography (SPECT) offered significantimprovements.27 SPECT still has a large installed equipment base andis widely used in the clinic for diagnostics in several disciplines inaddition to oncology.28-32 Temporal resolution and quantification ofSPECT was recently improved by the combination with computedtomography (CT). The adoption of PET cameras driven by the utilityof fluorine-18 (18F) fluorodeoxyglucose (18F-FDG) PET in oncologyhas resulted in another leap in spatial and temporal resolution basedon the physics of detecting coincident pairs rather than single gammarays.33-35 Most PET cameras routinely used with 18F-FDG are easilyadapted to work with other PET isotopes. Nuclear imaging of antibod-ies requires matching the radioactive half-life of the isotope to thetimescale of tumor antibody uptake (ie, using isotopes with half-lifeon order of days).36,37
Single-photon gamma-emitting radiometals including technetium-99m (99mTc), lutetium-177 (177Lu), yttrium-88 (88Y), and especiallyindium-111 (111In) have all been used to label mAbs for imaging,along with iodine isotopes (123I, 125I, and 131I). PET imaging of anti-bodies has been reported with isotopes including iodine-124 (124I),bromine-76 (76Br), yttrium-86 (86Y), and copper-64 (64Cu), but nonehave been as widely used as the radiometal zirconium-89 (89Zr).10,38
Our group at the University Medical Center Groningen has de-veloped to date five 89Zr-labeled antibodies for human use.39-43 Theprocedure has been robust, delivering more than 260 patient doses ondemand, with few labeling or logistic failures.
Depending on the radioisotope, different labeling methods areused. Iodines are often labeled directly to the antibody through simpleand widely available procedures, whereas radiometal ions are intro-duced indirectly by first conjugating a suitable chelator moiety to theantibody (typically using lysine groups) and then noncovalentlychelating the metal ion. Once antibodies have been internalized into
the tumor cells, they are subject to catabolism through lysosomaldegradation. The catabolites of radiometal ion chelates remaintrapped (residualized) inside the cells, leading to an accumulation ofradiometal (and PET signal) in the target tumor tissue over time. Incontrast, most iodine-containing catabolites are nonpolar moleculesthat are rapidly lost from the tumor cells, resulting in reduced tumorimage contrast at later time points.7 Iodine labels may thus be bestsuited for imaging noninternalizing targets.44,45 Characteristics ofSPECT and PET radionuclides regarding half-life, radiation exposure,and residualization properties are summarized in Table 2.
FROM SPECT AND PRECLINICAL PET TOCLINICAL IMMUNOPET
SPECT showed early success in assessing target presence and identify-ing tumor lesions both preclinically and clinically. Trastuzumab, bev-acizumab, the DR4 mAb mapatumumab, capromab penditide, andcG250 have all been labeled and imaged successfully with 111In inhumans (Table 2).
Many preclinical small animal studies have been performed with89Zr-labeled mAbs to determine their tumor targeting characteristics.Appendix Table A1 (online only) provides an overview of the 89Zr-labeled mAbs for preclinical research including scanning days andtumor types assessed.
Using knowledge obtained in these studies, translation toclinical tracers has been possible. Interestingly, with epidermalgrowth factor receptor (EGFR) – directed mAbs, there has been aninteresting disparity between efficacy, EGFR expression deter-mined by IHC, and tumor uptake as determined by the EGFR-targeting radiotracers.67-71
These studies point to the potential utility of complementingorgan-level PET imaging with microscopic-level fluorescence imagingto help explain these disparities. The first clinical imaging trial using89Zr-cetuximab PET imaging showed differential uptake among pa-tients. Larger studies are needed to determine the relation betweencetuximab dosing, efficacy, and tumor uptake.72
The clinical feasibility of using radiolabeled mAbs for tumorlocalization with PET was first demonstrated in nine patients withbreast cancer receiving 124I-labeled HMFGI, a murine mAb against amucin target on breast cancer cells. Scans at 1 to 4 days after injectionrevealed a higher uptake in the tumor compared with normal breasttissue.73 Subsequently, many mAbs have been labeled with PET iso-topes for clinical imaging. For example, 124I-labeled cG250 was ad-ministered to identify aggressive clear-cell renal cell carcinoma (RCC)before surgery in a phase I trial of 26 patients with a renal masssuspected to be malignant. In 15 of 16 patients with proven clear-cellcarbonic anhydrase IX (CAIX) –positive RCC histology, immunoPETidentified the tumor.61 A large number of patients (n � 195) withrenal masses underwent 124I-cG250 PET to identify the clear-cell RCCphenotype before surgery. Both sensitivity and specificity improvedcompared with conventional CT: 86% and 86% for immunoPETcompared with 75% and 47% for CT, respectively.62
On the basis of early successes, 89Zr has now been coupledwith 14 different mAbs for clinical use. For all mAbs, signal- andtumor-to-background ratios seem to be optimal 3 to 7 days aftertracer injection. Table 3 provides an overview of these mAbs andtheir clinical trials.
Antibody PET Imaging in Anticancer Drug Development
www.jco.org © 2015 by American Society of Clinical Oncology 1495
129.125.175.213Information downloaded from jco.ascopubs.org and provided by at Bibliotheek der Rijksuniversiteit on June 1, 2016 from
Copyright © 2015 American Society of Clinical Oncology. All rights reserved.
Tabl
e2.
Cha
ract
eris
tics
ofR
adio
nucl
ides
for
Ant
ibod
yIm
agin
gW
ithS
PE
CT
and
PE
Tin
Onc
olog
y
Rad
ionu
clid
eH
alf-
Life
(hou
rs)
Res
idua
lizat
ion
Adv
anta
geD
isad
vant
age
Rad
iatio
nD
ose
for
Typi
calD
iagn
ostic
Ant
ibod
yS
can
(app
roxi
mat
eam
ount
ofM
Bq
per
radi
atio
ndo
se)
Pro
duct
ion
Met
hod
Labe
led
toA
bsfo
rH
uman
Use
inO
ncol
ogy
SP
EC
T111In
67.3
Pos
itive
Long
T1⁄2
com
para
ble
toT1
⁄2
ofm
Abs
;in
vivo
char
acte
ristic
sco
mpa
rabl
eto
90Y
and
177Lu
for
RIT
Bon
e-se
ekin
gfr
ee1
11In
radi
onuc
lide
can
form
upon
cata
bolis
mof
antib
ody
0.21
mS
vpe
rM
Bq;
11
1In
-tra
stuz
umab
:15
0M
bqap
prox
imat
ely
equa
lto
30m
Sv;
11
1In
-bev
aciz
umab
:10
0M
Bq
appr
oxim
atel
yeq
ualt
o20
mS
v
Cyc
lotr
on:
prot
onirr
adia
tion
ofca
dmiu
m
Tras
tuzu
mab
,46
map
atum
umab
,47
beva
cizu
mab
,48,4
9ca
prom
abpe
ndet
ide,
50,5
1an
dcG
2505
2
131I
192.
5N
egat
ive
Inex
pens
ive,
read
ilyav
aila
ble
Hig
hra
diat
ion
expo
sure
beca
use
ofhi
ghga
mm
aen
ergy
and
appr
oxim
atel
y90
%�
deca
y(t
here
fore
also
ther
apeu
ticra
dioi
soto
pefo
rR
IT),
deha
loge
natio
n,th
yroi
dup
take
�
App
roxi
mat
ely
0.02
9m
Sv
per
MB
q;0.
6to
1.6
mC
itot
aldo
se(e
qual
to22
to59
MB
q)ap
prox
imat
ely
equa
lto
0.6
to1.
7m
Sv
Nuc
lear
reac
tor:
neut
ron
irrad
iatio
nof
natu
ral
tellu
rium
targ
et;
fissi
onpr
oduc
t
Tosi
tum
omab
,22
anti-
CE
A,5
3an
ti-hC
G,5
4an
ti-A
FP55†
123I
13.2
Neg
ativ
eLo
wer
radi
atio
ndo
seth
an131I,
bett
ersu
ited
for
thyr
oid
diag
nost
icsc
ans
Deh
alog
enat
ion,
thyr
oid
upta
ke,
rela
tivel
yex
pens
ive�
No
long
erus
edfo
rim
agin
gof
antib
odie
sC
yclo
tron
:pr
oton
irrad
iatio
nof
xeno
nH
MFG
1,H
MFG
256
99m
Tc6.
0P
ositi
veE
asily
avai
labl
eS
hort
T1⁄2
99
mTc
-DTP
Aeq
ualt
o0.
0049
mS
v/M
Bq
Nuc
lear
reac
tor:
99M
ode
cays
to99m
Tc;
99M
ois
crea
ted
byfis
sion
ofur
aniu
min
nucl
ear
reac
tors
CL-
5857
177Lu
159.
5P
ositi
veFo
rR
IT;
beca
use
ofga
mm
aem
issi
on,
imag
ing
also
poss
ible
Hig
hen
ergy
,hi
ghra
diat
ion
leve
l,no
tea
sily
avai
labl
eTh
erap
eutic
dose
:70
mC
i/M2
equa
lto
2,59
0M
Bq
Nuc
lear
reac
tor:
neut
ron
activ
atio
nJ5
91,5
8gi
rent
uxim
ab59
PE
T89Zr
78.4
Pos
itive
T1⁄2
com
para
ble
toT1
⁄2of
mA
bsE
xpen
sive
;bo
ne-s
eeki
ngfr
ee8
9Zr
radi
onuc
lide
can
form
upon
cata
bolis
mof
antib
ody,
part
icul
arly
inpr
eclin
ical
spec
ies
37M
Bq
appr
oxim
atel
yeq
ualt
o20
mS
v;74
MB
qap
prox
imat
ely
equa
lto
40m
Sv
Cyc
lotr
on:
prot
onirr
adia
tion
ofyt
triu
mD
etai
lslis
ted
inTa
ble
3
124I
100.
2N
egat
ive
T1⁄2
com
para
ble
toT1
⁄2of
mA
bsE
xpen
sive
,de
halo
gena
tion,
thyr
oid
upta
ke,
som
eve
ryhi
gh-e
nerg
yga
mm
ara
ys�
74M
Bq
appr
oxim
atel
yeq
ualt
o40
mS
vC
yclo
tron
:pr
oton
irrad
iatio
nof
tellu
rium
HuM
V83
3,60
cG25
0,61,6
2
HuA
3363
64C
u12
.7P
ositi
veN
ohi
gh-e
nerg
yga
mm
aem
issi
onG
iven
shor
ter
T1⁄2
suita
ble
for
imag
ing
frag
men
ts,
diab
odie
s,an
dot
her
engi
neer
edta
rget
ing
vect
ors;
not
easi
lyav
aila
ble
Ave
rage
effe
ctiv
edo
se�
0.03
6m
Sv/
MB
q;13
0M
Bq
appr
oxim
atel
yeq
ual
to4.
68m
Sv
Cyc
lotr
on:
prot
onirr
adia
tion
ofni
ckel
1A3:
mA
bta
rget
ing
lipid
antig
enin
CR
C64;
tras
tuzu
mab
65
86Y
‡14
.7P
ositi
veM
ainl
yin
com
bina
tion
with
90Y
-bas
edR
ITbe
caus
eof
high
posi
tron
emis
sion
Bon
e-se
ekin
gfr
ee8
6Y
/90Y
radi
onuc
lide
can
form
upon
cata
bolis
mof
antib
ody
Ther
apeu
ticdo
se:
15to
30M
Bq/
kgap
prox
imat
ely
equa
lto
913
to1,
827
mS
vfo
r70
-kg
patie
ntba
sed
on0.
87-m
Sv/
MB
qef
fect
ive
dose
Cyc
lotr
on:
prot
onirr
adia
tion
ofst
ront
ium
Ibrit
umom
abtiu
xeta
n66
76B
r‡16
.1N
egat
ive
Low
max
imum
posi
tron
ener
gy,
caus
ing
low
radi
atio
ndo
ses
and
bett
erim
agin
gre
solu
tion
Rel
ativ
ely
high
radi
atio
n,no
tea
sily
avai
labl
eN
AC
yclo
tron
:pr
oton
irrad
iatio
nof
sele
nium
Onl
ypr
eclin
ical
(con
tinue
don
follo
win
gpa
ge)
Lamberts et al
1496 © 2015 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
129.125.175.213Information downloaded from jco.ascopubs.org and provided by at Bibliotheek der Rijksuniversiteit on June 1, 2016 from
Copyright © 2015 American Society of Clinical Oncology. All rights reserved.
Tabl
e2.
Cha
ract
eris
tics
ofR
adio
nucl
ides
for
Ant
ibod
yIm
agin
gW
ithS
PE
CT
and
PE
Tin
Onc
olog
y(c
ontin
ued)
Rad
ionu
clid
eH
alf-
Life
(hou
rs)
Res
idua
lizat
ion
Adv
anta
geD
isad
vant
age
Rad
iatio
nD
ose
for
Typi
calD
iagn
ostic
Ant
ibod
yS
can
(app
roxi
mat
eam
ount
ofM
Bq
per
radi
atio
ndo
se)
Pro
duct
ion
Met
hod
Labe
led
toA
bsfo
rH
uman
Use
inO
ncol
ogy
18F‡
1.83
Neg
ativ
eE
asily
avai
labl
e;re
lativ
ely
shor
tpo
sitr
onra
nge
and
100%
posi
tron
yiel
den
able
rela
tivel
yhi
gh-
reso
lutio
nim
agin
gan
dhi
gh-s
ensi
tivity
dete
ctio
n
Giv
ensh
orte
rT1
⁄2su
itabl
efo
rim
agin
gfr
agm
ents
,di
abod
ies,
and
othe
ren
gine
ered
targ
etin
gve
ctor
s
NA
Cyc
lotr
on:
prot
onirr
adia
tion
ofox
ygen
Onl
ypr
eclin
ical
68G
a‡1.
13P
ositi
veG
ener
ator
prod
uced
(rel
ativ
ely
good
avai
labi
lity)
Giv
ensh
orte
rT1
⁄2su
itabl
efo
rim
agin
gfr
agm
ents
,di
abod
ies,
and
othe
ren
gine
ered
targ
etin
gve
ctor
s
NA
Cyc
lotr
on:
prot
onirr
adia
tion
ofzi
ncO
nly
prec
linic
al
Abb
revi
atio
ns:A
bs,a
ntib
odie
s;A
FP,�
-fet
opro
tein
;76B
r,br
omin
e-76
;CE
A,c
arci
noem
bryo
nic
antig
en;C
RC
,col
orec
talc
ance
r;6
4C
u,co
pper
-64;
DTP
A,—
diet
hyle
netr
iam
ine
pent
aace
ticac
id;1
8F,
fluor
ine-
18;6
8G
a,ga
llium
-68;
hCG
,hu
man
chor
ioni
cgo
nado
trop
in;
HM
FG,
hum
anm
ilk-f
at-g
lobu
le;
12
3I,
iodi
ne-1
23;
12
4I,
iodi
ne-1
24;
13
1I,
iodi
ne-1
31;
111In
,in
dium
-111
;177Lu
,lu
tetiu
m-1
77;
mA
b,m
onoc
lona
lan
tibod
y;99M
o,m
olyb
denu
m-9
9;N
A,
not
appl
icab
le;
PE
T,po
sitr
onem
issi
onto
mog
raph
y;R
IT,
radi
oim
mun
othe
rapy
;S
PE
CT,
sing
le-p
hoto
nem
issi
onco
mpu
ted
tom
ogra
phy;
T1⁄2,
term
inal
half-
life;
99m
Tc,
tech
netiu
m-9
9m;
86Y
,yt
triu
m-8
6;90Y
,yt
triu
m-9
0;89Zr
,zi
rcon
ium
-89.
�Th
yroi
dup
take
with
iodi
dera
dion
uclid
esis
prev
ente
dby
adeq
uate
bloc
kage
ofno
rmal
thyr
oid
tissu
ebe
fore
iodi
dera
dion
uclid
ein
ject
ion.
†Thi
slis
ting
ofan
tibod
ies
labe
led
with
131I
isno
tco
mpl
ete
but
serv
esas
illus
trat
ion.
‡The
sera
dion
uclid
esar
em
ainl
yus
edfo
rim
agin
gof
antib
ody
frag
men
tsan
dsm
alla
ntib
ody-
like
mol
ecul
esbe
caus
eof
thei
rsh
ort
T1⁄2.
Antibody PET Imaging in Anticancer Drug Development
www.jco.org © 2015 by American Society of Clinical Oncology 1497
129.125.175.213Information downloaded from jco.ascopubs.org and provided by at Bibliotheek der Rijksuniversiteit on June 1, 2016 from
Copyright © 2015 American Society of Clinical Oncology. All rights reserved.
An interesting early example was a tumor visualization study in14 patients with HER2-positive metastatic breast cancer. Tracer dosesof 89Zr-trastuzumab were administered with 10 mg of unlabeled (ie,cold) trastuzumab and appeared in the gut of trastuzumab-naivepatients but yielded excellent tumor images in patients already receiv-ing much higher cold trastuzumab doses for treatment. Increasing the
cold dose to 50 mg was necessary to acquire good images intrastuzumab-naive patients. Excellent 89Zr-trastuzumab tumor up-take revealed known HER2-positive tumor lesions in liver, lung, andbone. Moreover, unknown brain metastases were detected, demonstrat-ing delivery of antibody to brain metastases across a locally compro-mised blood–brain barrier.39 Trastuzumab clearance is dose
Table 3. 89Zr-Labeled Antibodies in Finalized or Ongoing Clinical Studies
Antibody Site Status ClinicalTrials.gov Identifier
BevacizumabPrimary BC UMCG Finished75 NCT00991978Metastatic BC UMCG Finished79 NCT01081613Inflammatory BC Dana-Farber Cancer Institute, Brigham and Women’s Hospital Boston Ongoing NCT01894451Metastatic RCC UMCG Finished40 NCT00831857
UMCG Ongoing NCT01028638Neuroendocrine tumors UMCG Finished85 NCT01338090VHL UMCG Finished NCT00970970MM UMCG Ongoing NCT01859234
TrastuzumabMetastatic BC UMCG Finished39 —
UMCG, Royal Marsden Hospital Finished79 NCT1081600Jules Bordet Institute, UZA, UMCG, VUmc, UMCN Ongoing89 NCT01565200Jules Bordet Institute Ongoing NCT01420146UMCG Ongoing NCT01832051UMCG, VUmc, UMCN Ongoing NCT01957332
BC Washington University School of Medicine Ongoing NCT02065609Esophagastric cancer MSKCC Ongoing NCT02023996
FresolimumabGlioblastoma UMCG Finished41 NCT01472731
U36HNSCC VUmc Finished91
CetuximabStage IV cancer Maastricht Radiation Oncology, VUmc Ongoing NCT00691548Metastatic colorectal cancer VUmc Finished72 NCT01691391
VUmc, UMCG, UMCN Ongoing NCT02117466HNSCC NKI-AVL, Maastricht University Medical Center, Karolinska Institutet,
Institut Catala de la Salut, Gustave Roussy, UMC UtrechtOngoing NCT01504815
RituximabB-cell lymphoma VUmc Ongoing NTR3392
OfatumumabB-cell lymphoma VUmc Ongoing NTR3392
HuJ591Metastatic prostate cancer MSKCC Finished73a NCT01543659
IAB2MMetastatic prostate cancer MSKCC Ongoing NCT01923727
MSTP2109A (STEAP1)Metastatic prostate cancer MSKCC Ongoing73b NCT01774071
RO5479599HER3-positive solid tumors UMCG Ongoing42 NCT01482377
RO5429083CD44-positive metastatic solid tumors VUmc, UMCN Finished NCT01358903
MMOT0530AOvarian or pancreatic cancer UMCG, VUmc Finished43 NCT01832116
Ibritumomab tiuxetanB-cell lymphoma VUmc Finished66 —
PanitumumabRefractory GI and urothelial
carcinomas, NSCLC, sarcomasNCI Ongoing NCT02192541
Abbreviations: BC, breast cancer; HER3, human epidermal growth factor receptor 3; HNSCC, head and neck squamous cell carcinoma; MM, multiple myeloma;MSKCC, Memorial Sloan-Kettering Cancer Center; NCI, National Cancer Institute; NSCLC, non–small-cell lung cancer; NKI-AVL, Nederlands Kanker Instituut Antonivan Leeuwenhoek; NTR, Nederlands Trial Register; RCC, renal cell cancer; STEAP1, six transmembrane epithelial antigen of prostate 1; UMCG, University MedicalCenter Groningen; UMCN, Radboud University Medical Center Nijmegen; UZA, Universitair Ziekenhuis Antwerpen; VHL, von Hippel–Lindau disease; VUmc, VrijeUniversity Medical Center; 89Zr, zirconium-89.
Lamberts et al
1498 © 2015 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
129.125.175.213Information downloaded from jco.ascopubs.org and provided by at Bibliotheek der Rijksuniversiteit on June 1, 2016 from
Copyright © 2015 American Society of Clinical Oncology. All rights reserved.
dependent. In this imaging study, we noticed that an additionalamount of predosed cold (ie, unlabeled) antibody was needed foradequate tumor visualization with immunoPET.39 89Zr-trastuzumabimaging has been used to resolve a clinical dilemma, in which HER2status was important, but a biopsy was impractical.74 A clinical trial isunder way to demonstrate utility in a larger patient population. Figure2 shows a representative 89Zr-trastuzumab PET scan. In another trial,patients receiving trastuzumab therapy were imaged with 64Cu-trastuzumab PET, showing primary breast, lymph node, andmetastatic lung lesions.65 Additional trials are ongoing with 64Cu-trastuzumab to determine the optimal dose and to assess the co-rrelation of tumor tracer uptake with IHC HER2 expression (ClinicalTrials.gov identifier NCT01093612 and NCT00605397). No head-to-head comparisons are yet available between 64Cu-trastuzumaband 89Zr-trastuzumab PET in patients, but the principal rationalefor using 64Cu rather than 89Zr would be that its shorter half-life(12.7 v 78.4 hours) could lower the patient radiation burden. Thismay be attainable where the optimal imaging time point is within 2days after injection.
Other whole-body patient data support the target-specificnature of the immunoPET signal; in histologically proven clear-cellRCC, all 124I-cG250 PET–positive lesions were CAIX positive.61 Inpatients with primary breast cancer, 89Zr-bevacizumab PET uptakecorrelated with vascular endothelial growth factor A (VEGF-A)expression determined by enzyme-linked immunosorbent assay(ELISA).75
TARGET MODULATION ASSESSED BY ANTIBODY IMAGING
Development of potential therapeutic agents can benefit greatly frombiomarkers of target modulation. This typically requires assessmentsbefore and after treatment. Given the timescales of radioactive decay,antibody pharmacokinetics, biodistribution, and tumor uptake, using111In-SPECT or 89Zr-immunoPET as a pharmacodynamic biomarker
allows a second imaging mAb injection approximately 14 days afterthe first.40,66 In 14 patients with RCC, 111In-bevacizumab SPECTvisualized tumors 7 days after tracer injection; reduced 111In-bevacizumab uptake was noted in all nine patients after 4 weeks ofneoadjuvant sorafenib treatment.48 111In-bevacizumab SPECT de-tected all known lymph node lesions in nine patients with stage III toIV melanoma at baseline. After one therapeutic dose of bevacizumab,a 21% reduction in tumor tracer uptake was observed. The tumoruptake in the second scan series correlated with VEGF-A levels mea-sured by IHC in the tumor tissue.49
Several imaging studies have examined the effects of modulatingheat shock protein 90 (HSP90) on its client proteins. Changes in HER2induced by HSP90 inhibitors in xenografts have been imaged withseveral reagents: F(ab=)2 trastuzumab fragments, full-length trastu-zumab, and a fast-clearing Z-domain PET tracer.75,77
Another effect of HSP90 inhibition—reduced VEGF secretion—was monitored by 89Zr-bevacizumab PET in VEGF-expressing xeno-grafts. Treatment resulted in a 44% signal decrease 6 days after tracerinjection. This reduction correlated with lowered tumor levels ofVEGF-A as measured by ELISA.78 Similar studies of HSP90 inhibitorshave been taken into the clinic, where patients with HER2-positivemetastatic breast cancer received 89Zr-trastuzumab scans before andafter three once-per-week doses of NVP-AUY922. Heterogeneoustumor uptake was observed at baseline, and a variety of effects wereseen in the post-treatment 89Zr- trastuzumab scans.79
MODULATION OF ANTIBODY DELIVERY TO TUMOR
Treatment with the VEGF mAb bevacizumab resulted in reducedVEGF activity and consequent reductions in vessel density and mac-romolecular permeability in preclinical models.80 Consistent withthese processes, 89Zr-PET in mouse xenograft models showed thatbevacizumab treatment reduced acute tumor uptake of 89Zr-labeledtrastuzumab, bevacizumab, and nonspecific immunoglobulin G.81
Fig 2. Zirconium-89–trastuzumab positronemission tomography/computed tomographyimages in patient with human epidermalgrowth factor receptor 2 –positive breast can-cer with multiple bone metastases in verte-brae and a large liver metastasis (transverse,sagittal, and coronal views).
Antibody PET Imaging in Anticancer Drug Development
www.jco.org © 2015 by American Society of Clinical Oncology 1499
129.125.175.213Information downloaded from jco.ascopubs.org and provided by at Bibliotheek der Rijksuniversiteit on June 1, 2016 from
Copyright © 2015 American Society of Clinical Oncology. All rights reserved.
Similar reductions in trastuzumab tumor uptake were reported inHER2-expressing xenografts in mice administered the anti-VEGFmAb B20-4.1, which cross reacts with both human and murineVEGF.82 Acute vascular effects of bevacizumab were also apparent inclinical studies. PET scans with 15O-H2O in patients with non–small-cell lung cancer showed rapid reduction in tumor perfusion after atherapeutic dose of bevacizumab, as well as a 34% lower 11C-docetaxeltumor uptake.83
In serial 89Zr-bevacizumab PET scans, patients with metastaticRCC receiving bevacizumab/interferon showed 47% less tumor up-take after 2 weeks of treatment, whereas a modest variable decreasewith sunitinib suggested different modes of action in these antiangio-genic therapies.40 A third antiangiogenic drug, the mammaliantarget of rapamycin inhibitor everolimus, also caused lower 89Zr-bevacizumab tracer uptake in mice bearing human ovarian cancerxenografts.84 In patients with neuroendocrine tumors, everolimustreatment also showed a decline in 89Zr-bevacizumab uptake by35%.85 These studies together suggest that 89Zr-bevacizumab PETcould be used as a biomarker of combined vascular permeability andVEGF levels after antiangiogenic therapy to determine tumor accessi-bility for subsequent treatment.
ANTIBODY IMAGING TO SUPPORT ANTIBODY DOSE FINDING
Pharmacokinetic studies of trastuzumab have shown that the clear-ance from blood is dose dependent and elevated in patients with hightumor burden.86 ImmunoPET with 89Zr-trastuzumab in patients hasadded to knowledge about tumor tissue kinetics and shown thatcurrent clinical practice may be underdosing trastuzumab. A patientwith metastatic breast cancer with extensive tumor load underwent89Zr-trastuzumab immunoPET before and during trastuzumab ther-apy. Initial scans showed high tracer uptake in liver metastases butinadequate visualization of known bone lesions and fully depletedblood levels. Imaging during trastuzumab therapy showed bothliver and bone metastases and persistence in the blood pool. Thisillustrates that a higher dose of mAb may be needed to optimizetumor delivery in patients with a high burden of antibody-internalizing tumor.87
Scouting experiments determine antibody distribution with animaging isotope to enable patient-specific radiation dosimetry calcu-lations before therapeutic RIT. 90Y is a high-energy beta-emittingisotope for RIT applications, whereas 86Y may be the ideal surrogateisotope for scouting because it is chemically identical to 90Y. In prac-tice, 89Zr-immunoPET may suffice; it effectively predicted the biodis-tribution of 90Y- and 177Lu-labeled cetuximab in a study of xenograftsexpressing EGFR.88 Clinical data indicating the utility of 89Zr in scout-ing come from immunoPET studies of 89Zr–ibritumomab tiuxetanbefore RIT with 90Y–ibritumomab tiuxetan. Seven relapsed pa-tients with CD20-positive B-cell non-Hodgkin lymphoma re-ceived 68 MBq 89Zr-ibritumomab tiuxetan and showed specifictumor uptake after 3 to 6 days. This was followed after 14 days by atherapeutic dose of 15 or 30 MBq/kg of 90Y–ibritumomab tiuxetanwith a coinjection of 89Zr–ibritumomab tiuxetan. The highest ab-sorbed 90Y dose, calculated from the 89Zr biodistribution, wasfound in the liver (3.2 � standard deviation of 1.8 mGy/MBq), andbiodistribution of 89Zr was not influenced by the simultaneous90Y–ibritumomab tiuxetan treatment.66
The utility of immunoPET for scouting RIT doses shouldextend to ADC therapies. Molecular imaging of unconjugatedmAbs could quantify tumor uptake and confirm adequate dosing.The processes driving tumor signal for imaging are the same asthose for drug delivery by an ADC—a combination of tissue expo-sure, tissue penetration, expression of target receptor, and anti-body internalization. Understanding these factors in patients willlikely encourage further use of whole-body 89Zr-immunoPET inthe development of ADC therapeutics. Recently, interim patient-based analysis during an ongoing trial in patients with HER2-positive metastatic breast cancer showed a negative predictivevalue of 89Zr-trastuzumab imaging for RECIST response to theHER2 ADC adotrastuzumab emtansine of 88%. When combinedwith 18F-FDG PET after one cycle of adotrastuzumab emtansine,the negative predictive value was 100%.89 A phase I study of anADC comprising a mesothelin mAb armed with the antimitoticdrug MMAE is being accompanied by a parallel trial using baseline89Zr scans with the naked antimesothelin antibody to quantifyantibody uptake in tumor lesions and ultimately to relate this toantitumor effects.43
COSTS AND CONSEQUENCES OF IMMUNOPET IMAGING
ImmunoPET can be costly, and its routine use requires appropriatejustification. Antibody labeling and a series of PET scans can costseveral thousand US dollars (highly dependent on country and insti-tution, with United States being more expensive than Europeansites).90 However, immunoPET is valuable for making good decisionson drug development investments and is valuable for providingwhole-body all-lesion information in patients. This informationwould be difficult to obtain even from multiple biopsies, which entailtheir own risks and costs.
ImmunoPET also seems to be safe. A dosimetry study ofionizing radiation, the principal hazard to which immunoPETpatients are exposed, was performed in 20 patients with head andneck squamous cell carcinoma who received 74.9 MBq (� stan-dard deviation of 0.6 MBq) of 89Zr-labeled U36 mAb without anyadverse events. The mean radiation whole-body dose in patientswas 40 mSv, which is comparable to two abdominal CTs.91 How-ever, new PET/CT scanners are more sensitive, so most clinicalstudies now use only 37 MBq 89Zr injected activity, with scansperformed 2 to 8 days later. Concerning tolerability, patient scan-ning times with 89Zr-labeled mAbs typically increase from 45 min-utes soon after injection to 90 minutes 1 week later.
FUTURE IMAGING APPLICATIONS IN DRUG DEVELOPMENT
Nuclear imaging will always have limitations imposed by the inev-itable radiation burden to patients, clinical staff, and caregivers andthe relatively high cost of dealing with nuclear reagents. Although itis not an alternative for whole-body nuclear imaging, optical im-aging with fluorescent dyes may acquire an important role in thenear future.
The utility of molecular-guided optical surgery was assessed in afeasibility study of patients with ovarian cancer who underwent deb-ulking surgery after injection of fluorescein isothiocyanate (FITC)
Lamberts et al
1500 © 2015 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
129.125.175.213Information downloaded from jco.ascopubs.org and provided by at Bibliotheek der Rijksuniversiteit on June 1, 2016 from
Copyright © 2015 American Society of Clinical Oncology. All rights reserved.
–labeled folate to target the folate receptor alpha (FR-�). Intraopera-tive imaging at 520 nm showed uptake in all FR-�–expressing tumorlesions (even tumor deposits � 1 mm).92 To reduce autofluorescencenoise, near-infrared fluorophores (NIRFs), which emit light at wave-lengths between 700 and 900 nm, are preferred.93
IRDye800CW is an NIRF suitable for producing conjugates un-der good manufacturing practices for patient injection. With bevaci-zumab and trastuzumab, it has yielded highly specific images ofxenograft tumors in mice using a real-time intraoperative clinicalprototype camera system. Results were compared with those obtainedwith 89Zr-immunoPET.94
The use of an IRDye800CW conjugate as the imaging agentopens up possibilities for multimodality imaging— both to imagein vivo and to look directly at microscopic mAb distribution inrelation to blood vessels, tumor cells, and its antigen targetdistribution. An ongoing trial in patients with primary breastcancer is evaluating safety, uptake, quantification, and localiza-tion of bevacizumab-IRDye800CW in tumor and normal tissues(ClinicalTrials.gov identifier NCT01508572). Dual-labeled anti-bodies (detectable by SPECT, PET, or NIRF) have been developedand used to facilitate the development and validation of multimo-dality imaging.95,96
Understanding cancer immunotherapies such as ipili-mumab and anti-PD1/PD-L1 mAbs may require dual-labeledreagents in patients, because target expression at the organ level(imaged by immunoPET) and distribution at the microscopiclevel (imaged by NIRF) are both fundamentally important tounderstanding the effects of these drugs.97 This will allow effi-cient use and better interpretation of valuable— but inherentlyvariable—patient tissue samples by enabling both overall tumoruptake measurement and histopathologic follow-up in thesame lesions.
Furthermore, small antibody fragments, such as nanobodies,have become interesting for in vivo imaging of cell activity, andthey have been proposed as theranostic tools for both diagnosticand targeted radionuclide therapy in oncology.98 Pretargeting isanother interesting technique in preclinical development, in whichantibody and radionuclide delivery are separated to reducesystemic radioactivity exposure. A bispecific antibody is firstadministered to target the tumor cell with one epitope, followedby administration of a radioisotope-bound peptide that bindsto the second isotope.99,100
DISCUSSION
This review demonstrates that immunoPET, especially 89Zr-immunoPET, is showing real promise as a biomarker in early clinicalmAb, ADC, and RIT trials. Complementing traditional histologicassessments of static target expression, immunoPET may reveal targetpresence, engagement, and internalization and directly demon-strate antibody uptake in tumor tissue in patients at the time oftheir treatment. This has the potential to provide prognostic andpredictive information, helping in the decision between antibody-based drug candidates and dosing regimens and in the selection ofappropriate patients for enrollment onto early clinical trials. Thewhole-body, all-lesion nature of immunoPET lends itself to ad-
dressing the increasingly recognized complexities of between- andwithin-lesion tumor heterogeneity.
Furthermore, pharmacologic proof of principle has been shownin some cases by measuring the mAb tumor uptake before and duringtreatment using immunoPET as a biomarker of response. Dose-finding studies could therefore be based on quantification of antibodyuptake as a function of antibody dose. For ADC candidates, immuno-PET studies in early development may inform the choice of target andantibody by revealing unexpected pharmacokinetic characteristics.For example, such studies could identify an organ that functions as asink (ie, collects large amount of tracer) and make predictions aboutorgan toxicity, because the premise of molecular targeting is to obtainstrongly selective tumor uptake. In addition, the biology of targetexpression and antibody uptake might be studied in the context ofacquired resistance and combination treatment strategies.
As with the adoption of other clinical technologies, the standard-ization of protocols for producing the reagents and acquiring, process-ing, and analyzing the 89Zr-immunoPET images will need robustmulticenter trials. Appropriate interpretation will depend on thought-ful comparisons of imaging results against traditional gold-standardmetrics of target expression, such as IHC obtained subsequent tobiopsies of imaged lesions.
Some potential confounding factors exist, particularly in tumorswith low target expression levels, in which vasculature and nonspecificuptake may contribute to the observed low-level signals. This places alower limit on the amount of antibody uptake that can be meaning-fully studied. Unraveling these contributions may require dynamicstudies in which the temporal patterns of uptake can be monitored;the internalization-driven signal is likely to increase progressively overtime, while static components such as blood volume remain relativelyconstant, and noninternalizing binding will plateau relatively early.Several recent studies have emphasized the collection of tumor biop-sies for measurement of protein expression of the target to correlatewith the PET signal, a step that should be encouraged to develop ourunderstanding of the imaging results.61,62,75
The half-life and stability of 89Zr mAb– based radiopharma-ceuticals lend themselves to centralized production and distribu-tion, facilitating collaborative multicenter studies. ImmunoPETtracers are powerful and practical tools for gaining more insightinto the mechanism of action, response, and treatment outcome ofantibody-based therapeutics.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTSOF INTEREST
Disclosures provided by the authors are available with this article atwww.jco.org.
AUTHOR CONTRIBUTIONS
Conception and design: Laetitia E. Lamberts, Simon P. Williams,Elisabeth G.E. de VriesCollection and assembly of data: Laetitia E. Lamberts, Simon P.Williams, Elisabeth G.E. de VriesData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authors
Antibody PET Imaging in Anticancer Drug Development
www.jco.org © 2015 by American Society of Clinical Oncology 1501
129.125.175.213Information downloaded from jco.ascopubs.org and provided by at Bibliotheek der Rijksuniversiteit on June 1, 2016 from
Copyright © 2015 American Society of Clinical Oncology. All rights reserved.
REFERENCES
1. Mathers CD, Loncar D: Projections of globalmortality and burden of disease from 2002 to 2030.PLoS Med 3:e442, 2006
2. Hanahan D, Weinberg RA: Hallmarks of can-cer: The next generation. Cell 144:646-674, 2011
3. Reichert JM, Valge-Archer VE: Developmenttrends for monoclonal antibody cancer therapeutics.Nat Rev Drug Discov 6:349-356, 2007
4. Teicher BA, Chari RV: Antibody conjugatetherapeutics: Challenges and potential. Clin CancerRes 17:6389-6397, 2011
5. Reichert JM: Antibodies to watch in 2013:Mid-year update. MAbs 4:513-517, 2013
6. Reichert JM, Wenger JB: Developmenttrends for new cancer therapeutics and vaccines.Drug Discov Today 13:30-37, 2008
7. Wu AM, Olafsen T: Antibodies for molecularimaging of cancer. Cancer J 14:191-197, 2008
8. Willmann JK, van Bruggen N, DinkelborgLM, et al: Molecular imaging in drug development.Nat Rev Drug Discov 7:591-607, 2008
9. Weissleder R, Pittet MJ: Imaging in the eraof molecular oncology. Nature 452:580-589, 2008
10. van Dongen GA, Poot AJ, Vugts DJ: PETimaging with radiolabeled antibodies and tyrosinekinase inhibitors: Immuno-PET and TKI-PET. TumourBiol 33:607-615, 2012
11. Keizer RJ, Huitema AD, Schellens JH, et al:Clinical pharmacokinetics of therapeutic monoclonalantibodies. Clin Pharmacokinet 49:493-507, 2010
12. Hogarth PM, Pietersz GA: Fc receptor-targeted therapies for the treatment of inflamma-tion, cancer and beyond. Nat Rev Drug Discov11:311-331, 2012
13. Robert C, Thomas L, Bondarenko I, et al:Ipilimumab plus dacarbazine for previously un-treated metastatic melanoma. N Engl J Med 364:2517-2526, 2011
14. Hamid O, Robert C, Daud A, et al: Safety andtumor responses with lambrolizumab (anti-PD-1) inmelanoma. N Engl J Med 369:134-144, 2013
15. Hamid O, Sosman JA, Lawrence DP, et al:Clinical activity, safety, and biomarkers of MPDL3280A,an engineered PD-L1 antibody in patients with locallyadvanced or metastatic melanoma (mM). J Clin Oncol31:550s, 2013 (suppl 15s; abstr 9010)
16. Wolchok JD, Kluger H, Callahan MK, et al:Nivolumab plus ipilimumab in advanced melanoma.N Engl J Med 369:122-133, 2013
17. Di Fede G, Bronte G, Rizzo S, et al: Mono-clonal antibodies and antibody fragments: State ofthe art and future perspectives in the treatment ofnon-haematological tumors. Expert Opin Biol Ther11:1433-1445, 2011
18. Wittrup KD, Thurber GM, Schmidt MM, et al:Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol 503:255-268,2012
19. Ravandi F, Estey EH, Appelbaum FR, et al:Gemtuzumab ozogamicin: Time to resurrect? J ClinOncol 30:3921-3923, 2012
20. Gualberto A: Brentuximab vedotin (SGN-35),an antibody-drug conjugate for the treatment ofCD30-positive malignancies. Expert Opin InvestigDrugs 21:205-216, 2012
21. Verma S, Miles D, Gianni L, et al: Trastu-zumab emtansine for HER2-positive advancedbreast cancer. N Engl J Med 19:1783-1791, 2012
22. Goldsmith SJ: Radioimmunotherapy of lym-phoma: Bexxar and zevalin. Semin Nucl Med 40:122-135, 2010
23. Pospisilova S, Gonzalez D, Malcikova J, et al:ERIC recommendations on TP53 mutation analysisin chronic lymphocytic leukemia. Leukemia 26:1458-1461, 2012
24. Tan DS, Thomas GV, Garrett MD, et al:Biomarker-driven early clinical trials in oncology: Aparadigm shift in drug development. Cancer J 15:406-420, 2009
25. Gerlinger M, Rowan AJ, Horswell S, et al:Intratumor heterogeneity and branched evolutionrevealed by multiregion sequencing. N Engl J Med366:883-892, 2012
26. Sawyers CL: The cancer biomarker problem.Nature 452:548-552, 2008
27. Mach JP, Buchegger F, Forni M, et al: Use ofradiolabeled monoclonal anti-CEA antibodies for thedetection of human carcinomas by external photo-scanning and tomoscintigraphy. Immunol Today2:239-249, 1981
28. Douketis JD, Ginsberg JS, Haley S, et al:Accuracy and safety of 99mTc-labeled anti-D-dimer(DI-80B3) fab’ fragments (ThromboView(R)) in thediagnosis of deep vein thrombosis: A phase II study.Thromb Res 3:381-389, 2012
29. Prior JO, Farhad H, Muller O: Multimodalityimaging in ischemic cardiomyopathy. Curr Cardio-vasc Imaging Rep 7:9285, 2014
30. Rischpler C, Nekolla S, Schwaiger M: PETand SPECT in heart failure. Curr Cardiol Rep 15:337,2013
31. Sharifi S, Nederveen AJ, Booij J, et al: Neu-roimaging essentials in essential tremor: A system-atic review. Neuroimage Clin 5:217-231, 2014
32. Booth TC, Nathan M, Waldman AD, et al:The role of functional dopamine-transporter SPECTimaging in parkinsonian syndromes, part 2. AJNRAm J Neuroradiol [epub ahead of print on June 12,2014]
33. Czernin J, Phelps ME: Positron emissiontomography scanning: Current and future applica-tions. Annu Rev Med 53:89-112, 2002
34. Nayak TK, Brechbiel MW: Radioimmunoim-aging with longer-lived positron-emitting radionu-clides: Potentials and challenges. Bioconjug Chem20:825-841, 2009
35. Histed SN, Lindenberg ML, Mena E, et al:Review of functional/anatomical imaging in oncol-ogy. Nucl Med Commun 33:349-361, 2012
36. Verel I, Visser GW, Boellaard R, et al: 89Zrimmuno-PET: Comprehensive procedures for theproduction of 89Zr-labeled monoclonal antibodies. JNucl Med 44:1271-1281, 2003
37. van Dongen GA, Vosjan MJ: Immuno-positron emission tomography: Shedding light onclinical antibody therapy. Cancer Biother Radiop-harm 25:375-385, 2010
38. Kaur S, Venktaraman G, Jain M, et al: Recenttrends in antibody-based oncologic imaging. CancerLett 315:97-111, 2012
39. Dijkers EC, Oude Munnink TH, Kosterink JG,et al: Biodistribution of 89Zr-trastuzumab and PETimaging of HER2-positive lesions in patients withmetastatic breast cancer. Clin Pharmacol Ther 87:586-592, 2010
40. Oosting SF, Brouwers AH, van Es SC, et al:89Zr-bevacizumab PET visualizes heterogeneoustracer accumulation in tumor lesions of renal cellcarcinoma patients and differential effects of anti-angiogenic treatment. J Nucl Med 56:63-69, 2015
41. den Hollander MW, Bensch F, GlaudemansAWJM, et al: 89Zr-GC1008 PET imaging andGC1008 treatment of recurrent glioma patients. JClin Oncol 31:126s, 2013 (suppl 15s; abstr 2050)
42. Bensch F, Lamberts LE, Lub-de Hooge MN,et al: Phase I imaging study of the HER3 antibodyRG7116 using 89Zr-RG7116-PET in patients withmetastatic or locally advanced HER3-positive solidtumors. J Clin Oncol 32:718s, 2014 (suppl 15s; abstr11095)
43. Lamberts LE, Menke-van der Houven vanOordt CW, Bensch F, et al: PET-imaging with 89Zr-labeled anti-mesothelin antibody in patients withpancreatic of ovarian cancer. Ann Oncol 25, 2014(abstr 1627P)
44. Hnatowich DJ, Layne WW, Childs RL, et al:Radioactive labeling of antibody: A simple and effi-cient method. Science 220:613-615, 1983
45. Malmberg J, Sandström M, Wester K, et al:Comparative biodistribution of imaging agents for invivo molecular profiling of disseminated prostatecancer in mice bearing prostate cancer xenografts:Focus on 111In- and 125I-labeled anti-HER2 human-ized monoclonal trastuzumab and ABY-025 affibody.Nucl Med Biol 38:1093-1102, 2011
46. Perik PJ, Lub-De Hooge MN, Gietema JA, etal: Indium-111-labeled trastuzumab scintigraphy inpatients with human epidermal growth factor recep-tor 2-positive metastatic breast cancer. J Clin Oncol24:2276-2282, 2006
47. Oldenhuis C, Dijkers EC, Duiker EW, et al:Development of radiolabeled mapatumumab andimaging in solid tumor patients who are treated withgemcitabine, cisplatin, and mapatumumab. J ClinOncol 27:67e, 2009 (suppl; abstr e14521)
48. Desar IM, Stillebroer AB, Oosterwijk E, et al:111In-bevacizumab imaging of renal cell cancer andevaluation of neoadjuvant treatment with the vascu-lar endothelial growth factor receptor inhibitorsorafenib. J Nucl Med 51:1707-1715, 2010
49. Nagengast WB, Hooge MN, van Straten EM,et al: VEGF-SPECT with 111In-bevacizumab in stageIII/IV melanoma patients. Eur J Cancer 47:1595-1602, 2011
50. Ellis RJ, Kaminsky DA, Zhou EH, et al: Ten-year outcomes: The clinical utility of single photonemission computed tomography/computed tomog-raphy capromab pendetide (prostascint) in a cohortdiagnosed with localized prostate cancer. Int J Ra-diat Oncol Biol Phys 81:29-34, 2011
51. Wong WW, Schild SE, Vora SA, et al: Image-guided radiotherapy for prostate cancer: A prospectivetrial of concomitant boost using indium-111-capromabpendetide (ProstaScint) imaging. Int J Radiat Oncol BiolPhys 81:e423-e429, 2011
52. Brouwers AH, Buijs WC, Oosterwijk E, et al:Targeting of metastatic renal cell carcinoma with thechimeric monoclonal antibody G250 labeled with131I or 111In: An intrapatient comparison. Clin CancerRes 9:3953S-3960S, 2003
53. Goldenberg DM, DeLand F, Kim E, et al: Useof radiolabeled antibodies to carcinoembryonic anti-gen for the detection and localization of diversecancers by external photoscanning. N Engl J Med298:1384-1386, 1978
54. Goldenberg DM, Kim EE, DeLand FH, et al:Clinical radioimmunodetection of cancer with radio-active antibodies to human chorionic gonadotropin.Science 208:1284-1286, 1980
55. Goldenberg DM, Kim EE, Deland F, et al:Clinical studies on the radioimmunodetection oftumors containing alpha-fetoprotein. Cancer 45:2500-2505, 1980
56. Epenetos AA, Britton KE, Mather S, et al:Targeting of iodine-123-labelled tumour-associatedmonoclonal antibodies to ovarian, breast, and gas-trointestinal tumours. Lancet 2:999-1005, 1982
Lamberts et al
1502 © 2015 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
129.125.175.213Information downloaded from jco.ascopubs.org and provided by at Bibliotheek der Rijksuniversiteit on June 1, 2016 from
Copyright © 2015 American Society of Clinical Oncology. All rights reserved.
57. Yao YF, Yang Z, Li ZF, et al: Immunoscintig-raphy of local recurrent rectal cancer with 99mTc-labeled anti-CEA monoclonal antibody CL58. WorldJ Gastroenterol 13:1841-1846, 2007
58. Tagawa ST, Milowsky MI, Morris MJ, et al:Phase II study of lutetium-177 labeled anti-prostate-specific membrane antigen (PSMA) monoclonal an-tibody J591 for metastatic castration-resistantprostate cancer. Clin Cancer Res 7:5182-5191, 2013
59. Stillebroer AB, Franssen GM, Mulders PF, etal: ImmunoPET imaging of renal cell carcinoma with124I- and 89Zr-labeled anti-CAIX monoclonal antibodycG250 in mice. Cancer Biother Radiopharm 28:510-515, 2013
60. Jayson GC, Zweit J, Jackson A, et al: Molec-ular imaging and biological evaluation of HuMV833anti-VEGF antibody: Implications for trial design ofantiangiogenic antibodies. J Natl Cancer Inst 94:1484-1493, 2002
61. Divgi CR, Pandit-Taskar N, Jungbluth AA, etal: Preoperative characterisation of clear-cell renalcarcinoma using iodine-124-labelled antibody chime-ric G250 (124I-cG250) and PET in patients with renalmasses: A phase I trial. Lancet Oncol 8:304-310,2007
62. Divgi CR, Uzzo RG, Gatsonis C, et al: Posi-tron emission tomography/computed tomographyidentification of clear cell renal cell carcinoma: Re-sults from the REDECT trial. J Clin Oncol 31:187-194, 2013
63. Carrasquillo JA, Pandit-Taskar N, O’DonoghueJA, et al: 124I-huA33 antibody PET of colorectal cancer.J Nucl Med 52:1173-1180, 2011
64. Philpott GW, Schwarz SW, Anderson CJ, etal: RadioimmunoPET: Detection of colorectal carci-noma with positron-emitting copper-64-labeledmonoclonal antibody. J Nucl Med 36:1818-1824,1995
65. Tamura K, Kurihara H, Yonemori K, et al:64Cu-DOTA-trastuzumab-PET imaging in patientswith HER2-positive breast cancer. J Clin Oncol 30:660s, 2012 (suppl; abstr 10519)
66. Rizvi SN, Visser OJ, Vosjan MJ, et al: Biodis-tribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients withrelapsed B-cell non-hodgkin’s lymphoma using 89Zr-ibritumomab tiuxetan and PET. Eur J Nucl Med MolImaging 39:512-520, 2012
67. Aerts HJ, Dubois L, Perk L, et al: Disparitybetween in vivo EGFR expression and 89Zr-labeledcetuximab uptake assessed with PET. J Nucl Med50:123-131, 2009
68. Ray GL, Baidoo KE, Wong KJ, et al: Preclin-ical evaluation of a monoclonal antibody targetingthe epidermal growth factor receptor as a radioim-munodiagnostic and radioimmunotherapeutic agent.Br J Pharmacol 157:1541-1548, 2009
69. Niu G, Sun X, Cao Q, et al: Cetuximab-basedimmunotherapy and radioimmunotherapy of headand neck squamous cell carcinoma. Clin Cancer Res16:2095-2105, 2010
70. Niu G, Li Z, Xie J, et al: PET of EGFR antibodydistribution in head and neck squamous cell carci-noma models. J Nucl Med 50:1116-1123, 2009
71. Nayak TK, Garmestani K, Baidoo KE, et al:Preparation, biological evaluation, and pharmacoki-netics of the human anti-HER1 monoclonal antibodypanitumumab labeled with 86Y for quantitative PETof carcinoma. J Nucl Med 51:942-950, 2010
72. Menke CW, Gootjes EC, Huisman MC, et al:ImmunoPET imaging with 89Zr-cetuximab in pa-
tients with advanced colorectal cancer. J Clin Oncol32:720s, 2014 (suppl 15s; abstr 11102)
73. Wilson CB, Snook DE, Dhokia B, et al: Quan-titative measurement of monoclonal antibody distri-bution and blood flow using positron emissiontomography and 124iodine in patients with breastcancer. Int J Cancer 47:344-347, 1991
73a. Pandit-Taskar N, O’Donoghue JA, BeylergilV, et al: 89Zr-huJ591 immuno-PET imaging in pa-tients with advanced metastatic prostate cancer.Eur J Nucl Med Mol Imaging 41:2093-2105, 2014
73b. Carrasquillo JA, Danila DC, Beylergil V, et al:Initial PET imaging and pharmacokinetic results froma phase I/II study of Zr-89-labeled anti-STEAP1 anti-body in metastatic castrate-resistant prostate can-cer (mCRPC) patients. 105th Annual Meeting of theAmerican Association for Cancer Research, SanDiego, CA, April 5-9, 2014 (abstr 2069)
74. Gaykema SB, Brouwers AH, Hovenga S, etal: Zirconium-89-trastuzumab positron emission to-mography as a tool to solve a clinical dilemma in apatient with breast cancer. J Clin Oncol 30:e74-e75,2012
75. Gaykema SB, Brouwers AH, Lub-de HoogeMN, et al: 89Zr-bevacizumab PET imaging in primarybreast cancer. J Nucl Med 54:1014-1018, 2013
76. Terwisscha van Scheltinga AGT, Lub-de HoogeMN, Abiraj K, et al: ImmunoPET and biodistribution withhuman epidermal growth factor receptor 3 targetingradiolabeled antibody 89Zr-GE-huMAb-HER3. Eur J Can-cer 48:96-97, 2012
77. Gill HS, Tinianow JN, Ogasawara A, et al: Amodular platform for the rapid site-specific radiola-beling of proteins with 18F exemplified by quantita-tive positron emission tomography of humanepidermal growth factor receptor 2. J Med Chem52:5816-5825, 2009
78. Nagengast WB, de Korte MA, Oude Mun-nink TH, et al: 89Zr-bevacizumab PET of early anti-angiogenic tumor response to treatment withHSP90 inhibitor NVP-AUY922. J Nucl Med 51:761-767, 2010
79. Gaykema SBM, Schröder CP, Vitfell-Rasmussen J, et al: 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the heatshock protein 90 inhibitor NVP-AUY922 in meta-static breast cancer patients. Clin Cancer Res 20:3945-3954, 2014
80. Jain RK: Normalizing tumor vasculature withanti-angiogenic therapy: A new paradigm for combi-nation therapy. Nat Med 7:987-989, 2001
81. Arjaans M, Oude Munnink TH, Oosting SF,et al: Bevacizumab-induced normalization of bloodvessels in tumors hampers antibody uptake. CancerRes 73:3347-3355, 2013
82. Pastuskovas CV, Mundo EE, Williams SP, etal: Effects of anti-VEGF on pharmacokinetics, biodis-tribution, and tumor penetration of trastuzumab in apreclinical breast cancer model. Mol Cancer Ther11:752-762, 2012
83. Van der Veldt AA, Lubberink M, Bahce I, etal: Rapid decrease in delivery of chemotherapy totumors after anti-VEGF therapy: Implications forscheduling of anti-angiogenic drugs. Cancer Cell21:82-91, 2012
84. van der Bilt AR, Terwisscha van ScheltingaAG, Timmer-Bosscha H, et al: Measurement oftumor VEGF-A levels with 89Zr-bevacizumab PET asan early biomarker for the antiangiogenic effect ofeverolimus treatment in an ovarian cancer xenograftmodel. Clin Cancer Res 18:6306-6314, 2012
85. van Asselt SJ, Oosting SF, Brouwers AH, etal: Everolimus reduces 89Zr-bevacizumab tumor up-take in patients with neuroendocrine tumors. J NuclMed 55:1087-1092, 2014
86. Bruno R, Washington CB, Lu JF, et al: Pop-ulation pharmacokinetics of trastuzumab in patientswith HER2� metastatic breast cancer. Cancer Che-mother Pharmacol 56:361-369, 2005
87. Oude Munnink TH, Dijkers EC, Netters SJ, et al:Trastuzumab pharmacokinetics influenced by extent hu-man epidermal growth factor receptor 2–positive tumorload. J Clin Oncol 28:e355-e356, 2010
88. Perk LR, Visser GW, Vosjan MJ, et al: (89)Zras a PET surrogate radioisotope for scouting biodis-tribution of the therapeutic radiometals (90)Y and(177)Lu in tumor-bearing nude mice after coupling tothe internalizing antibody cetuximab. J Nucl Med46:1898-1906, 2005
89. Gebhart G, Lamberts LE, Garcia C, et al: PET/CTwith 89Zr-trastuzumab and 18F-FDG to individualize treat-ment with trastuzumab emtansine (T-DM1) in metastaticHER2 positive breast cancer (mBC). J Clin Oncol 32:695s, 2014 (suppl 15s; abstr 11001)
90. Langer A: A systematic review of PET andPET/CT in oncology: A way to personalize cancertreatment in a cost-effective manner? BMC HealthServ Res 10:283, 2010
91. Borjesson PK, Jauw YW, de Bree R, et al:Radiation dosimetry of 89Zr-labeled chimeric mono-clonal antibody U36 as used for immuno-PET inhead and neck cancer patients. J Nucl Med 50:1828-1836, 2009
92. van Dam GM, Themelis G, Crane LM, et al:Intraoperative tumor-specific fluorescence imagingin ovarian cancer by folate receptor-� targeting: Firstin-human results. Nat Med 17:1315-1319, 2011
93. Frangioni JV: New technologies for humancancer imaging. J Clin Oncol 26:4012-4021, 2008
94. Terwisscha van Scheltinga AG, van DamGM, Nagengast WB, et al: Intraoperative near-infrared fluorescence tumor imaging with vascularendothelial growth factor and human epidermalgrowth factor receptor 2 targeting antibodies. J NuclMed 52:1778-1785, 2011
95. Azhdarinia A, Ghosh P, Ghosh S, et al: Dual-labeling strategies for nuclear and fluorescence mo-lecular imaging: A review and analysis. Mol ImagingBiol 14:261-276, 2012
96. Cohen R, Vugts DJ, Stigter-van Walsum M,et al: Inert coupling of IRDye800CW andzirconium-89 to monoclonal antibodies for single- ordual-mode fluorescence and PET imaging. Nat Pro-toc 8:1010-1018, 2013
97. Sliwkowski MX, Mellman I: Antibody thera-peutics in cancer. Science 341:1192-1198, 2013
98. D’Huyvetter M, Xavier C, Caveliers V, et al:Radiolabeled nanobodies as theranostic tools intargeted radionuclide therapy of cancer. Expert OpinDrug Deliv 11:1939-1954, 2014
99. Sharkey RM, Karacay H, Litwin S, et al:Improved therapeutic results by pretargeted radio-immunotherapy of non-Hodgkin’s lymphoma with anew recombinant, trivalent, anti-CD20, bispecificantibody. Cancer Res 68:5282-5290, 2008
100. Sharkey RM, Karacay H, Johnson CR, et al:Pretargeted versus directly targeted radioimmuno-therapy combined with anti-CD20 antibody consoli-dation therapy of non-Hodgkin lymphoma. J NuclMed 50:444-453, 2009
■ ■ ■
Antibody PET Imaging in Anticancer Drug Development
www.jco.org © 2015 by American Society of Clinical Oncology 1503
129.125.175.213Information downloaded from jco.ascopubs.org and provided by at Bibliotheek der Rijksuniversiteit on June 1, 2016 from
Copyright © 2015 American Society of Clinical Oncology. All rights reserved.
GLOSSARY TERMS
antibody-drug conjugate: an antibody chemically linkedto a therapeutic cytotoxic agent providing targeted delivery of thecytotoxic agent preferentially to cancer cells expressing the anti-gen recognized by the antibody.
antigen: a substance that promotes, or is the target of, an im-mune response.
immunohistochemistry: the application of antigen-antibody interactions to histochemical techniques. Typically, atissue section is mounted on a slide and incubated with antibod-ies (polyclonal or monoclonal) specific to the antigen (primaryreaction). The antigen-antibody signal is then amplified using asecond antibody conjugated to a complex of peroxidase-antiperoxidase, avidin-biotin-peroxidase, or avidin-biotinalkaline phosphatase. In the presence of substrate and chro-mogen, the enzyme forms a colored deposit at the sites ofantibody-antigen binding. Immunofluorescence is an alternateapproach to visualize antigens. In this technique, the primaryantigen-antibody signal is amplified using a second antibodyconjugated to a fluorochrome. On ultraviolet light absorption,the fluorochrome emits its own light at a longer wavelength(fluorescence), thus allowing localization of antibody-antigencomplexes.
monoclonal antibody: an antibody that is secreted from a singleclone of an antibody-forming cell. Large quantities of monoclonal anti-bodies are produced from hybridomas, which are produced by fusingsingle antibody-forming cells to tumor cells. The process is initiatedwith initial immunization against a particular antigen, stimulating theproduction of antibodies targeted to different epitopes of the antigen.Antibody-forming cells are subsequently isolated from the spleen. Byfusing each antibody-forming cell to tumor cells, hybridomas can eachbe generated with a different specificity and targeted against a differentepitope of the antigen.
pharmacodynamics: the study of the biochemical and physiologiceffects of a drug on the body.
pharmacokinetics: a branch of pharmacology that studies the rela-tionship between drug exposure level, time course of exposure, and theoverall response of an organism. Although pharmacokinetics is largelyapplied to drugs, it is also applicable to other compounds such as nutri-ents, toxins, hormones, etc. Pharmacokinetics is subdivided into ab-sorption and disposition (distribution, metabolism, and excretion) andis generally referred to as ADME (absorption, distribution, metabolism,excretion). With respect to drugs administered, all processes occur intandem once a drug dose is administered. In clinical trials, phase I stud-ies will typically study pharmacokinetics and safety of the drug.
Lamberts et al
1504 © 2015 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
129.125.175.213Information downloaded from jco.ascopubs.org and provided by at Bibliotheek der Rijksuniversiteit on June 1, 2016 from
Copyright © 2015 American Society of Clinical Oncology. All rights reserved.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Antibody Positron Emission Tomography Imaging in Anticancer Drug Development
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships areself-held unless noted. I � Immediate Family Member, Inst � My Institution. Relationships may not relate to the subject matter of this manuscript. For moreinformation about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or jco.ascopubs.org/site/ifc.
Laetitia E. LambertsNo relationship to disclose
Simon P. WilliamsEmployment: GenentechStock or Other Ownership: RochePatents, Royalties, Other Intellectual Property: Genentech holds IP onsite-specific antibody labeling technologies (Inst)
Anton G.T. Terwisscha van ScheltingaNo relationship to disclose
Marjolijn N. Lub-de HoogeNo relationship to disclose
Carolien P. SchröderNo relationship to disclose
Jourik A. GietemaResearch Funding: Roche (Inst), Abbvie (Inst), Siemens (Inst)
Adrienne H. BrouwersNo relationship to disclose
Elisabeth G.E. de VriesResearch Funding: Roche (Inst), Genentech (Inst), Novartis (Inst),Amgen (Inst)
Antibody PET Imaging in Anticancer Drug Development
www.jco.org © 2015 by American Society of Clinical Oncology
129.125.175.213Information downloaded from jco.ascopubs.org and provided by at Bibliotheek der Rijksuniversiteit on June 1, 2016 from
Copyright © 2015 American Society of Clinical Oncology. All rights reserved.
Appendix
Table A1. Preclinical Studies Evaluating Specific-Tumor Accumulation and Biodistribution of Different 89Zr-Labeled mAbs in Human Tumor–Bearing Mice or Rats
mAb Target
Model
Tumor Assessment
Scanning MomentsTumor Target–Specific
UptakeAnimalModel Tumor Location Type Location
Bevacizumab (Nagengast WB,et al: J Nucl Med 48:1313-1319, 2007)
VEGF Mice Subcutaneous SKOV3 human ovariancancer cell line
VEGF positive Days 1 to 7 (optimaldays 3 and 7)
Present; 89Zr-IgG controlshows lower uptake
Trastuzumab (Dijkers EC, et al:J Nucl Med 50:974-981,2009)
HER2 Mice Subcutaneous SKOV3 human ovariancancer cell line
HER2 positive Days 1 to 6 Present; HER2-negativecell line GLC4 showslower uptake
Cetuximab67 EGFR Mice Subcutaneous Different EGFR-expressing humancell lines
1 to 120 hours (optimalat 72 hours)
Higher uptake inintermediate-expressing cell linescompared with high�
Panitumumab (Nayak TK, et al:J Nucl Med 53:113-120,2012)
EGFR Mice Subcutaneouspulmonary andintraperitoneal
EGFR-expressing humancolorectal cancer cellline LS-174T
Days 1 to 6 Present; higher uptakein LS-174T than innegative cell lineA375 (humanmalignant melanoma)
R1507 (Heskamp S, et al: JNucl Med 51:1565-1572,2010)
IGF-1R Mice Subcutaneous SUM1249 human triple-negative breastcancer cell line
Days 1 to 7 No comparison with IgGor IGF-1R–negativecell line
Capromab pendetide (7E11;Ruggiero A, et al: J NuclMed 52:1608-1615, 2011)
PSMA Mice Subcutaneous PSMA-positive humancancer cell lines
1 to 120 hours (optimalat 72 hours)
No comparison with IgGor PSMA-negativecell line
DN30 (Perk LR, et al: Eur JNucl Med Mol Imaging35:1857-1867, 2008)
c-MET Mice Subcutaneous GLT-16 human gastriccarcinoma cell line;FaDu mouse-cellcarcinoma
c-MET positive andnegative
Days 1 to 4 Present; higher uptakein GLT-16 with 89Zr-DN30 than with 124I-DN30 and comparedwith c-Met–negativecell line
Fresolimumab (Oude MunninkTH, et al: J Nucl Med 52:2001-2008, 2011)
TGF-� Mice Subcutaneous andmetastaticmodel
CHO clones with TGF-�MDA-MB-231
Days 1 to 7 No difference in 89Zr-fresolimumabcompared with 111In-IgG uptake becauseof presence of onlylatent TGF-� insteadof active
RO5323441 (Oude MunninkTH, et al: J Nucl Med 54:929-935, 2013)
PlGF Mice Huh-7; ACHN PlGF positive andnegative
Days 1 to 7 Present; compared with111In-IgG andcompared with PlGF-negative cell line
AMA (Ter Weele EJ, et al:104th Annual Meeting ofthe American Associationfor Cancer Research,Washington, DC, April 6-10, 2013 [abstr 2659])
MSLN Mice Subcutaneous HPAC and CAPAN-2 MSLN positive Days 1 to 6 (optimalday 6)
Present; higher uptakeof 89Zr-AMA than111In-IgG
RG711676 HER3 Mice Subcutaneous Four different HER3-expressing cell lines
Days 1 to 6 (optimalday 6)
Present; higher uptakein higher HER3-expressing tumors
cG250 (girentuximab; BrouwersA, et al: Cancer BiotherRadiopharm 19:155-163,2004)
CAIX Nude rats Subcutaneous RCC cell line SK-RC-52 5 minutes and 1, 2,and 3 days
Increasing tumor uptakeover time; nocomparison with IgGor CAIX-negativetumor
Abbreviations: AMA, antimesothelin antibody; CAIX, carbonic anhydrase IX; c-MET, anti-mesenchymal epithelial transition factor; 64Cu, copper-64; EGFR, epidermalgrowth factor receptor; HER2, human epidermal growth factor receptor 2; HER3, human epidermal growth factor receptor 3; 124I, iodine-124; IGF-1R, insulin-likegrowth factor 1 receptor; IgG, immunoglobulin G; 111In, indium-111; mAb, monoclonal antibody; MSLN, mesothelin; PlGF, placental growth factor; PSMA,prostate-specific membrane antigen; RCC, renal cell cancer; TGF-�, transforming growth factor beta; VEGF, vascular endothelial growth factor; 86Y, yttrium-86; 89Zr,zirconium-89.
�Disparity between efficacy, EGFR expression determined by immunohistochemistry, and tumor uptake is known as determined by EGFR-targeting radiotracers89Zr-cetuximab, 64Cu-cetuximab, 64Cu-panitumumab, 86Y-panitumumab, and 111In-panitumumab (Dijkers EC, et al: J Nucl Med 50:974-981, 2009; Nayak TK, et al:J Nucl Med 53:113-120, 2012; Heskamp S, et al: J Nucl Med 51:1565-1572, 2010).58,67
Lamberts et al
© 2015 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
129.125.175.213Information downloaded from jco.ascopubs.org and provided by at Bibliotheek der Rijksuniversiteit on June 1, 2016 from
Copyright © 2015 American Society of Clinical Oncology. All rights reserved.